真迈生物董事长颜钦：“从0到1”这个过程没有0.5

Core Viewpoint - The article highlights the journey of Zhenmai Biotechnology in developing a domestically produced gene sequencer, overcoming significant challenges in a field dominated by foreign companies, and achieving substantial growth and innovation in the industry [1][2]. Company Overview - Zhenmai Biotechnology, founded in 2012, has become one of only three companies globally capable of providing full-flow sequencing instruments, achieving 100% self-research and production of core materials [1][3]. - The company has developed the world's fastest second-generation sequencer, FASTASeq S, which significantly reduces detection times for infections and tumors [6]. Financial Performance - The company reports an average annual revenue growth of 80% to 90%, with projected revenue nearing 400 million yuan this year, reaching a break-even point [1][6]. - Future annual performance growth is expected to maintain between 60% and 80% [1][6]. Technological Challenges - The development of gene sequencers involves complex innovations across over 20 disciplines, including optics, fluid mechanics, and biochemistry, with any shortcomings potentially impacting sequencing accuracy and costs [2][4]. - The industry faces a challenge in defining standards, as the current benchmarks have been set by dominant players like Illumina, which Zhenmai aims to surpass [7]. Market Strategy - Zhenmai's strategy includes a focus on building a closed-loop system that integrates devices, reagents, and ecological systems, which is crucial for gaining market acceptance and establishing a competitive edge [8]. - The company has expanded its international presence, with overseas revenue accounting for 50% and partnerships in over 60 countries [8]. Vision for the Future - The company's vision is to transition from "Made in China" to an internationally recognized brand, aiming to influence global standards and quality in the biotechnology sector [9].